Læknablaðið

Árgangur

Læknablaðið - 15.07.2012, Blaðsíða 14

Læknablaðið - 15.07.2012, Blaðsíða 14
RANNSÓKN Heimildir 1. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13(7 Suppl): S170-7. 2. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19-32. 3. Hágg S, Lindblom Y, Mjömdal T, Adolfsson R. High preva- lence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8. 4. Birkenaes AB, Sogaard AJ, Engh JA, Jonsdottir H, Ringen PA, Vaskinn A, et al. Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population. J Clin Psychiatry 2006; 67: 425-33. 5. Medical Illness and Schizophrenia. Ed. Meyer J, Nasrallah H. Arlington, American Psychiatric Publishing, 2003. 6. McEvoy JP, Brown S. Smoking in first-episode patients with schizophrenia. Am J Psychiatry 1999; 156:1120-1. 7. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 2010; 17:460 -6. 8 Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60:358-63. 9. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697-701. 10. Davidson S, Judd F, Jolley D, Hocking B, Thompson S, Hyland B. Cardiovascular risk factors for people with mental illness. Aust NZ J Psychiatr 2001; 35:196-202. 11. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15-22. 12. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000; 26: 903-12. 13. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Shoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157:975-81. 14. Mclntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychol 2001; 46: 273-81. 15. Handbók Hjartavemdar 2008 - hjarta.is 16. Meyer JM, Stahl SM. The metabolic syndrome and schi- zophrenia. Acta Psychiatr Scand 2009; 119:4-14. Review. ENGLISH SUMMARY A study of risk factors for cardiovascular disease among schizophrenic patients using the rehabilitation mental health services at Kleppur Sveinsson O12, Thorleifsson K', Aspelund Th34, Kolbeinsson H' Background: Studies have shown that schizophrenic patients die on average 15-20 years earlier than the normal population, and that increased prevalance of cardiovascular risk factors plays a crucial role Schizophrenic patients are underdiagnosed and undertreated when it comes to diabetes, hypertension and dyslipidemia. The aim of this study was to investigate the prevalence of metabolic syndrome, obesity, hypertension, diabetes and dyslipidemia among schizophrenic patients in lceland. Methods: An observational study of 106 schizophrenic patients in lceland during the period 2007-2009. The results were compared to age adjusted population based data. Results: 106 patients participated, 86 men and 20 women. In all 57% were diagnosed with metabolic syndrome (p<0.0001) in comparison to 14.1% in the general population. In all 73% were smokers (21% in the general population) p<0.0001 and 23.6% had hypertension of which only 20% were treated with anti-hypertensive medication. The average systolic blodpressure was 134.8 mmHg <0.001. In all 15.1% had a fasting glucose over 7 mmol/l but only 38% were previously diagnosed with diabetes. The average BMI was 29.7 kg/m2 p=0.0007, 45.3% were obese (BMI >30 kg/m2). Only 32.1% had normal BMI, and 82.1% had waist circumference over the normal limits. Conclusion: The physical condition of lcelandic schizophrenic patients is poor and their risk for cardiovascular diseases is high. It is necessary to follow their weight, blood pressure, blood glucose and lipids more closely It is imperative to educate and enable the schizophrenic patient to live a healthier life Correspondence: Ólafur Sveinsson, olafur.sveinsson@karolinska.se Key words: Metabolic syndrome, hypertension, diabetes, prevalence, schizophrenia, dyslipidemia. ’Rehabilitation Mental Health Services, The National University Hospital of lceland, 2Department of Neurology, Karolinska University Hospital, Stockholm, Sweden, 3lcelandic Heart Association, ‘University of lceland 402 LÆKNAblaðið 2012/98

x

Læknablaðið

Beinir tenglar

Ef þú vilt tengja á þennan titil, vinsamlegast notaðu þessa tengla:

Tengja á þennan titil: Læknablaðið
https://timarit.is/publication/986

Tengja á þetta tölublað:

Tengja á þessa síðu:

Tengja á þessa grein:

Vinsamlegast ekki tengja beint á myndir eða PDF skjöl á Tímarit.is þar sem slíkar slóðir geta breyst án fyrirvara. Notið slóðirnar hér fyrir ofan til að tengja á vefinn.